A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase
Related Experiment Video
Updated: Mar 30, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Yingying Zuo1, Yanxia Shi2, Xitao Li1
1Key Laboratory of Chemical Genomics, Key Laboratory of Structural Biology, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, China 518055.
Abstract:
As a critical regulator of the B-cell receptor signaling pathway, Bruton's tyrosine kinase (Btk) has attracted intensive drug discovery efforts for treating B-cell lineage cancers and autoimmune disorders. In particular, covalent inhibitors targeting Cys481 in Btk have demonstrated impressive clinical benefits, and their companion affinity probes have been crucial in the drug development process. Recently, we have discovered a novel series of 2,5-diaminopyrimidine-based covalent irreversible inhibitors of Btk. Here, we present the discovery of a novel affinity Btk probe based on the aforementioned scaffold and demonstrate its usage in evaluating the target engagement of Btk inhibitors in live cells.
Insights
Researchers developed a new Bruton
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Biochemistry
Background:
- Bruton's tyrosine kinase (Btk) is a key regulator in B-cell receptor signaling, making it a target for treating B-cell cancers and autoimmune diseases.
- Covalent inhibitors targeting Btk's Cys481 residue have shown clinical success, with affinity probes aiding their development.
Purpose of the Study:
- To discover and characterize a novel affinity probe for Bruton's tyrosine kinase (Btk).
- To utilize the novel probe for assessing the target engagement of Btk inhibitors in cellular models.
Main Methods:
- Design and synthesis of a novel 2,5-diaminopyrimidine-based scaffold for Btk inhibition.
- Development of an affinity probe derived from the identified inhibitor scaffold.
- Application of the affinity probe in live-cell assays to evaluate Btk inhibitor target engagement.
Main Results:
- A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase (Btk) was successfully developed.
- The probe demonstrated utility in evaluating the target engagement of Btk inhibitors within live cells.
Conclusions:
- The newly developed Btk affinity probe, based on a 2,5-diaminopyrimidine scaffold, is a valuable tool for drug discovery.
- This probe facilitates the assessment of Btk inhibitor efficacy and target engagement in relevant biological systems.
